Abstract
Iron supplementation therapy seems almost indispensable in adequate management of the patients with end - stage renal disease on maintenance hemodialysis, since at least one and a half grams iron is considered to be required per year to keep sufficient erythropoiesis. Iron supplementation in conjunction with erythropoietic-stimulating agents is widely carried out as a standard therapy. However, definite diagnosis of iron deficiency in hemodialysis patients is often difficult since serum ferritin levels increase frequently by various reasons including inflammation and malignancy. Although several guidelines to treat anemia of the hemodialysis patients have been proposed, they seem still insufficient and careful clinical observation is required in individual patient to avoid possible complications of iron overload. We, here, reassess the adequate iron supplementation therapy in those patients, and the necessity of new guideline employing recent advances including magnetic resonance imaging – based method (FerriScan) and hemoglobin content per each reticulocyte is also discussed.
Keywords: Erythropoietic-stimulating agents, end-stage renal disease, ferritin, iron, hemodialysis, iron deficiency, iron supplementation, iron overload.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Iron Supplementation Therapy in End-Stage Renal Disease Patients on Maintenance Hemodialysis
Volume: 13 Issue: 3
Author(s): Masanori Shibata and Shinkichi Taniguchi
Affiliation:
Keywords: Erythropoietic-stimulating agents, end-stage renal disease, ferritin, iron, hemodialysis, iron deficiency, iron supplementation, iron overload.
Abstract: Iron supplementation therapy seems almost indispensable in adequate management of the patients with end - stage renal disease on maintenance hemodialysis, since at least one and a half grams iron is considered to be required per year to keep sufficient erythropoiesis. Iron supplementation in conjunction with erythropoietic-stimulating agents is widely carried out as a standard therapy. However, definite diagnosis of iron deficiency in hemodialysis patients is often difficult since serum ferritin levels increase frequently by various reasons including inflammation and malignancy. Although several guidelines to treat anemia of the hemodialysis patients have been proposed, they seem still insufficient and careful clinical observation is required in individual patient to avoid possible complications of iron overload. We, here, reassess the adequate iron supplementation therapy in those patients, and the necessity of new guideline employing recent advances including magnetic resonance imaging – based method (FerriScan) and hemoglobin content per each reticulocyte is also discussed.
Export Options
About this article
Cite this article as:
Shibata Masanori and Taniguchi Shinkichi, Iron Supplementation Therapy in End-Stage Renal Disease Patients on Maintenance Hemodialysis, Cardiovascular & Hematological Disorders-Drug Targets 2013; 13 (3) . https://dx.doi.org/10.2174/1871529X1303140129155609
DOI https://dx.doi.org/10.2174/1871529X1303140129155609 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Severe Influenza: Clinical Features and Treatment Options
Current Respiratory Medicine Reviews Fc-independent Phagocytosis: Implications for IVIG and other Therapies in Immune-mediated Thrombocytopenia
Cardiovascular & Hematological Disorders-Drug Targets Sleep Disordered Breathing: Alternatives to CPAP Therapy
Current Respiratory Medicine Reviews Platelet in Progression of Atherosclerosis: A Potential Target in Diabetic Patients
Current Diabetes Reviews Obesity Modulation - The Role in Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Recent Applications of Triazolopyrimidine-Based Bioactive Compounds in Medicinal and Agrochemical Chemistry
Mini-Reviews in Medicinal Chemistry Potential Anti-cancer Drugs Commonly Used for Other Indications
Current Cancer Drug Targets Safety of Nanoparticles in Medicine
Current Drug Targets The Role of Diabetes Mellitus in Diseases of the Gallbladder and Biliary Tract
Current Diabetes Reviews The Rapidly Changing Composition of the Global Street Drug Supply and its Effects on High-risk Groups for COVID-19
Current Psychopharmacology Malaria and artemisinin derivatives: an updated review
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: Non-Reproductive Effects of Sex Steroids: Their Immunoregulatory Role (Guest Editor: Jorge Morales-Monto)]
Current Topics in Medicinal Chemistry Nitric Oxide-Derived Oxidants with a Focus on Peroxynitrite: Molecular Targets,Cellular Responses and Therapeutic Implications
Current Pharmaceutical Design Prospects for Developing New Antibacterials Targeting Bacterial Type IIA Topoisomerases
Current Topics in Medicinal Chemistry Catheter Ablation of Lone Atrial Fibrillation
Current Pharmaceutical Design Lipoprotein Like Nanoparticles Used in Drug and Gene Delivery
Current Pharmaceutical Design Painful Peripheral Neuropathies
Current Neuropharmacology Mechanism of Cardiac Pathogenesis and Cardiotoxicity of Anti- COVID-19 Drugs
Coronaviruses Epidemiological and Clinical Data of Amniotic Fluid Embolism in Forensic Settings
Current Pharmaceutical Biotechnology Statins in Aortic Disease
Current Pharmaceutical Design